1-4 of 4
Samit Hirawat
Close
Sort by
Journal Articles

Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.

Marina Savelieva, Praz, Dr., sc., math., Margaret M. Woo, Harald A. Weber, MD, Samit Hirawat, MD, Sofia Paul, PhD, Joanne Schindler, Roland Fisch, PhD
Journal: Blood
Blood (2009) 114 (22): 3780.
https://doi.org/10.1182/blood.V114.22.3780.3780
Published: 2009
Journal Articles

Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant.

Anas Younes, MD, Tee-Chuan Ong, MD, Vincent Ribrag, MD, Andreas Engert, MD, Dina Ben-Yehuda, MD, Robin McCabe, Angela Shen, MD, Christophe Le Corre, Samit Hirawat, MD, Anna Sureda, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 923.
https://doi.org/10.1182/blood.V114.22.923.923
Published: 2009
Journal Articles

Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589).

Rong Lin, MD, Jing Hu, PhD, Sofia Paul, PhD, Joanne Schindler, Margaret M. Woo, Stan Spence, PhD, Samit Hirawat, MD, Harald A. Weber, MD
Journal: Blood
Blood (2009) 114 (22): 2740.
https://doi.org/10.1182/blood.V114.22.2740.2740
Published: 2009
Journal Articles

Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).

Madeleine Duvic, Jürgen C. Becker, Stephane Dalle, Francisco Vanaclocha, Maria Grazia Bernengo, Celeste Lebbé, Reinhard Dummer, Samit Hirawat, Lei Zhang, Miriam Marshood, Glen Laird, H. Miles Prince
Journal: Blood
Blood (2008) 112 (11): 1005.
https://doi.org/10.1182/blood.V112.11.1005.1005
Published: 2008